Abstract:With a 5-year survival rate of approximately 10%, pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies in humans. A poor understanding of the underlying biology has resulted in a lack of effective targeted therapeutic strategies. Tissue microarray and bioinformatics analyses have revealed that the downstream transcriptional coactivator of the Hippo pathway, transcriptional coactivator with PDZ-binding motif (TAZ), might be a therapeutic target in PDAC. Since pharmacological inhibition of TAZ is challenging, we performed unbiased deubiquitinase (DUB) library screening to explore the pivotal regulators of TAZ ubiquitination as potential targets in PDAC models. We found that USP14 contributed to Yes-associated protein (YAP)/TAZ transcriptional activity and stabilized TAZ but not YAP. Mechanistically, USP14 catalyzed the K48-linked deubiquitination of TAZ to promote TAZ stabilization. Moreover, TAZ facilitated the transcription of USP14 by binding to the TEA domain transcription factor (TEAD) 1/4 response element in the promoter of USP14. USP14 was found to modulate the expression of TAZ downstream target genes through a feedback mechanism and ultimately promoted cancer progression and liver metastasis in PDAC models in vitro and in vivo. In addition, depletion of USP14 led to proteasome-dependent degradation of TAZ and ultimately arrested PDAC tumour growth and liver metastasis. A strong positive correlation between USP14 and TAZ expression was also detected in PDAC patients. The small molecule inhibitor of USP14 catalytic activity, IU1, inhibited the development of PDAC in subcutaneous xenograft and liver metastasis models. Overall, our data strongly suggested that the self-amplifying USP14-TAZ loop was a previously unrecognized mechanism causing upregulated TAZ expression, and identified USP14 as a viable therapeutic target in PDAC.

LKB1/AMPK axis crosstalks with Wnt/-catenin signaling in cancer via the deubiquitinase USP10

The Deubiquitinase USP10 Mediates Crosstalk Between the LKB1/AMPK Axis and Wnt/β-catenin Signaling in Cancer.

Correction to: USP20 positively regulates tumorigenesis and chemoresistance through β-catenin stabilization

Deubiquitination and Activation of AMPK by USP10.

USP10 strikes down β-catenin by dual-wielding deubiquitinase activity and phase separation potential

USP10 strikes down 8-catenin by dual-wielding deubiquitinase activity and phase separation potential

USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51-AKT signaling.

USP10 Suppresses Tumor Progression by Inhibiting Mtor Activation in Hepatocellular Carcinoma.

Posttranslational regulation of liver kinase B1 in human cancer

The E2F1/USP11 positive feedback loop promotes hepatocellular carcinoma metastasis and inhibits autophagy by activating ERK/mTOR pathway

Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway

Recent progress on liver kinase B1 (LKB1): expression, regulation, downstream signaling and cancer suppressive function.

Modulation Of Beta-Catenin Signaling By The Inhibitors Of Map Kinase, Tyrosine Kinase, And Pi3-Kinase Pathways

The interaction of canonical Wnt/β-catenin signaling with protein lysine acetylation

LKB 1 / AMPK / Mtor Signaling Pathway in Non-small-cell Lung Cancer

Wnt/β-catenin signaling regulates amino acid metabolism through the suppression of CEBPA and FOXA1 in liver cancer cells

Beclin1 Controls the Levels of P53 by Regulating the Deubiquitination Activity of USP10 and USP13

A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma

Wnt‐induced deubiquitination FoxM1 ensures nucleus β‐catenin transactivation

Dysregulation of Wnt/β-catenin signaling by protein kinases in hepatocellular carcinoma and its therapeutic application

AMP‐activated Protein Kinase Regulates Cancer Cell Growth and Metabolism Via Nuclear and Mitochondria Events